Quick Takeaways
- CITADEL ADVISORS LLC filed SCHEDULE 13G for Acrivon Therapeutics, Inc. Common Stock, par value $0.001 per share (the "Shares") (ACRV).
- Disclosed ownership: 5.5%.
- Date of event: 14 Nov 2025.
Quoteable Key Fact
"CITADEL ADVISORS LLC disclosed 5.5% ownership in Acrivon Therapeutics, Inc. Common Stock, par value $0.001 per share (the "Shares") (ACRV) on 14 Nov 2025."
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Citadel Advisors LLC | 4.9% | 1,541,326 | 0 | 1,541,326 | /s/ Seth Levy | Seth Levy, Authorized Signatory | |
| Citadel Advisors Holdings LP | 4.9% | 1,541,326 | 0 | 1,541,326 | /s/ Seth Levy | Seth Levy, Authorized Signatory | |
| Citadel GP LLC | 4.9% | 1,541,326 | 0 | 1,541,326 | /s/ Seth Levy | Seth Levy, Authorized Signatory | |
| Citadel Securities LLC | 0.6% | 180,541 | 0 | 180,541 | /s/ Seth Levy | Seth Levy, Authorized Signatory | |
| Citadel Securities Group LP | 0.6% | 180,541 | 0 | 180,541 | /s/ Seth Levy | Seth Levy, Authorized Signatory | |
| Citadel Securities GP LLC | 0.6% | 180,541 | 0 | 180,541 | /s/ Seth Levy | Seth Levy, Authorized Signatory | |
| Kenneth Griffin | 5.5% | 1,721,867 | 0 | 1,721,867 | /s/ Seth Levy | Seth Levy, attorney-in-fact* |